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Abstract 
Diabetes is one of the greatest public health challenges to face Australia. It is already 
Australia‟s leading cause of kidney failure, blindness (in those under 60 years) and lower 
limb amputation, and causes significant cardiovascular disease. Australia‟s diabetes 
amputation rate is one of the worst in the developed world, and appears to have significantly 
increased in the last decade, whereas some other diabetes complication rates appear to have 
decreased. This paper aims to compare the national burden of disease for the four major 
diabetes-related complications and the availability of government funding to combat these 
complications, in order to determine where diabetes foot disease ranks in Australia. Our 
review of relevant national literature indicates foot disease ranks second overall in burden of 
disease and last in evidenced-based government funding to combat these diabetes 
complications. This suggests public funding to address foot disease in Australia is 
disproportionately low when compared to funding dedicated to other diabetes complications. 
There is ample evidence that appropriate government funding of evidence-based care 
improves all diabetes complication outcomes and reduces overall costs. Numerous diverse 
Australian peak bodies have now recommended similar diabetes foot evidence-based 
strategies that have reduced diabetes amputation rates and associated costs in other developed 
nations. It would seem intuitive that “it‟s time” to fund these evidence-based strategies for 
diabetes foot disease in Australia as well. 
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Background 
Diabetes has been coined the „Black Death of the 21st century‟ due to its stark similarities 
with the 14
th
 century plague in terms of the rapid increase in global prevalence, morbidity and 
mortality [1]. In 2004, the global forecast of people with diabetes was estimated at 366 
million by 2030 [2]. Alarmingly this figure (equivalent to 8.3% of the world‟s adult 
population) was reached in 2011 almost 20 years earlier than expected [3]. The updated 2030 
estimate is now a staggering 552 million people (10% of the world‟s adult population) [3]. 
These disturbing figures prompted the United Nations to convene only the second ever UN 
General Assembly summit on a health issue in 2011 [4]. The summit resulted in 193 nations 
unanimously agreeing to adopt a Political Declaration on diabetes and other non-
communicable diseases that commits them to take action to urgently stem the tide of diabetes 
and its consequences [4,5]. 
Diabetes is characterised by high blood glucose levels, which can result in significant 
morbidity and mortality from macrovascular and microvascular complications including heart 
attack, stroke, kidney failure, blindness and lower limb amputation [5-7]. The significance of 
the complications faced by people with diabetes is emphasised by the fact that someone in the 
world dies from diabetes-related complications every seven seconds [5] and diabetes is now 
the leading cause of kidney failure and lower limb amputations globally [7]. In alignment 
with the overall increase in diabetes prevalence, healthcare expenditure on diabetes is 
expected to rise significantly from $US465 billion in 2011 to $US595 billion in 2030 [5]. 
This has prompted the World Economic Forum to identify diabetes as a global risk for 
business [5]. 
Australia is far from immune from the increasing impact of diabetes, with experts suggesting 
that it presents one of the most significant public health challenges Australia has ever faced 
[7,8]. Australia currently has over 1 million people diagnosed with diabetes [9], representing 
7.4% of the adult population [6]. An estimated additional 500,000 Australians have diabetes 
but remain undiagnosed [7]. By 2025, it is estimated that 2.5 to 3 million Australians will 
have diabetes [10,11]. This is equivalent to one in every three adults developing diabetes in 
their lifetime. [10,11]. The consequences of diabetes in Australia are significant with over 
500,000 hospital admissions (8% of all admissions) and 12,000 deaths (9% of all deaths) 
attributable to the condition in 2004 alone [6]. Consistent with global reports diabetes is the 
leading cause of kidney disease and lower limb amputation in Australia [7,12], resulting in 
increased length of hospital stay [6] and a cost of approximately $A6 billion in 2003 [13]. 
Successive Australian Governments have not ignored the „silent pandemic‟ of diabetes. 
Diabetes was announced as the fifth National Health Priority Action (NHPA) area in 1996 
and as such governments have invested in strategic plans, best-practice guidelines, 
medications, consumables, service programs, research and educational campaigns in an 
attempt to optimise care and reduce the impact of related complications [14,15]. The first 
National Diabetes Strategic Plan (1998) identified over 60 recommendations aimed at 
reducing the prevalence of diabetes and its complications [15]. This strategic plan strongly 
urged implementing a suite of nationally coordinated priority programs aimed at tackling 
individual diabetes complications in particular [15]. These proposed national programs 
included a visual impairment prevention program, end stage renal disease prevention 
program, cardiovascular disease prevention program and a foot disease management program 
[15]. The plan went further and expressly outlined it expected a 50% reduction in all 
diabetes-related end-stage complications within a decade with the implementation of all 
programs [15]. 
Despite these best intentions, a recent paper published in the Medical Journal of Australia by 
the Australian Diabetes Society has suggested that Australia‟s diabetes-related amputation 
numbers have increased by 30% between 1998 and 2005 and that Australia has failed to 
successfully implement key best-practice recommendations outlined for the management of 
diabetes-related foot disease [16]. More recent data suggests that diabetes-related amputation 
rates (per 100,000 general population) have also increased in Australia by over 30% for the 
period between 1998 and 2011 [17-19]. By comparison a recently released national diabetes 
indicator report shows a 30% reduction in vision loss over a similar period [17]. Furthermore, 
the same report indicates that new rates of end stage foot complications (amputations) are up 
to four times higher than that of new end-stage kidney disease [17]. 
The apparent disparity between rates and outcomes for foot disease compared to other 
diabetes-related complications prompted the authors to consider whether this correlates to an 
inequality in the level of government funding foot disease receives. Thus, this paper aims to 
firstly compare the national burden of disease for different diabetes-related complications and 
secondly the availability of government funding to combat these complications, in order to 
determine specifically where diabetes-related foot disease ranks in terms of disease burden 
and government spending . 
National burden and funding of diabetes complications 
Successive Australian governments have overseen the implementation of multi-faceted 
strategies in an attempt to turn the tide of diabetes over the last fifteen years. The National 
Health & Medical Research Council (NHMRC) has taken the lead on the development of 
best-practice guidelines and recommendations designed to encourage health systems and 
professionals to improve the management of diabetes and its complications [20-23]. 
Australian governments have attempted to complement these guidelines by funding best-
practice diabetes management recommendations via its Medical Benefits Schedule (MBS), 
Pharmaceutical Benefits Scheme (PBS) and other nationally funded programs aimed at 
tackling diabetes complications. With the release of multiple national government data 
reports [6,17] and successive research publications over the last decade [24-32], it is timely to 
compare the impact of these strategies on diabetes complication rates, costs, burden of 
disease and public health funding in Australia. 
A review of relevant national diabetes complication-related literature published over the last 
15 years forms the basis of this paper. Publications reviewed included government reports, 
epidemiological publications, health economic publications, evidence-based guidelines, 
government media releases, Medicare and Pharmaceutical Benefits Schemes. 
Table 1 displays the prevalence rates of diabetes-related high-risk complications, history of 
acute end stage complications (“acute complications”), new annual incidence of acute end 
stage complications, hospital admissions, average length of stay, deaths and burden of disease 
found in people with diabetes in Australia. For the purposes of this paper, we have defined 
„high-risk complications‟ as those diabetes-related complications (e.g. peripheral neuropathy, 
chronic kidney disease, retinopathy or heart failure) that place a person at high-risk of 
developing a more serious acute end stage diabetes complication (i.e. amputation, end stage 
renal disease, blindness or myocardial infarction respectively). 
Table 1 Comparison of specific adult diabetes complication rates, hospitalisations, deaths and burden of disease in Australia 
 High-risk
a
 Acute complications Hospitalisation Burden of disease 
 Population* Service** History - 
population
b*
 
History – 
service
c**
 [25] 
New –Service 
c**
 [25] 
Admissions
d
 
[6] 
ALOS 
d
 
[6] 
Deaths
d
 
[6] 
Burden Dx 
e
 
(DALY) 
f
 [6] 
CVD 21% [31] 40% [32] NA 14.0% 4.3% 93,110 NA 7,617 74,687 
Kidney 16% [30] 28% [25] 0.3% [30] 1.5% 0.3% 102,000 9 1,557 2,483 
Eyes 15% [28] 29% [25] 2.1% [28] 0.9% 0.7% 38,700 NA NA 1,258 
Foot 20% [27] 25% [25] 2.1% [27] 1.5% 0.6% 59,240 12-26 1,705 18,544 
ALOS: average length of stay; CVD: cardiovascular disease; DALY: disability adjusted life years; NA: not available 
*Population: Figures are taken from a population based study 
**Service: Figures are taken from a service-based study 
a
 High Risk: CVD (coronary heart disease, cerebrovascular disease, peripheral vascular disease), Kidney (chronic kidney disease stage 3, 
eGFR < 60 ml/min per 1.73 m2), Eyes (retinopathy), Foot (peripheral neuropathy, peripheral arterial disease) 
b
 Acute Complication History – Population based: Kidney (chronic kidney disease stage 4 & 5, eGFR < 30 ml/min per 1.73 m2), Eyes 
(proliferative diabetes retinopathy), Foot (foot ulcer) 
c
 Acute Complication History – Service based: CVD (myocardial infarct, cerebral stroke), Kidney (end stage renal disease, eGFR < 30 ml/min 
per 1.73 m
2
), Eyes (blindness), Foot (lower limb amputation) 
d
 Hospitalisation: CVD (coronary heart disease, stroke), Kidney (chronic kidney failure), Eyes (retinopathy, glaucoma, cataract), Foot 
(peripheral neuropathy, peripheral vascular disease, foot ulcer, lower limb amputation) 
e
 Burden of disease: CVD (ischaemic heart disease, stroke), Kidney (renal failure), Eyes (retinopathy), Foot (peripheral neuropathy, peripheral 
vascular disease, foot ulcer, lower limb amputation) 
f
 DALY: Healthy life years lost in terms of illness, injury and premature death. DALY combines years of life lost to premature death and years 
of healthy life lost due to non-fatal health outcomes 
How many people are affected by the different diabetes complications in 
Australia? 
Diabetes contributes significantly to cardiovascular, kidney, eye and foot disease [5,7]. 
Alarmingly, diabetes is now Australia‟s leading cause of kidney failure, blindness (in people 
under 60 years) [7] and lower limb amputation [12]; accounting for 17% of all blindness, 
32% of all end stage kidney failure and 60% of all amputations [6,12]. Recent reports suggest 
Australia has one of the worst diabetes-related lower limb amputation rates in the developed 
world [12,33,34], at nearly 20 per 100,000 people with diabetes [17,18,34] compared to an 
average of 12 per 100,000 people with diabetes in the developed world [33]. 
Our analysis suggest that foot disease ranks second overall to cardiovascular disease in terms 
of numbers of people affected by a high-risk or acute complication in the Australian 
population with diabetes (Table 1). Further figures suggest new acute complication cases are 
approximately 18 per 100,000 people per year for amputation and blindness, compared to six 
per 100,000 per year for end stage renal disease [17]. 
How much health care resource do different diabetes complications use in 
Australia? 
Foot disease ranks third behind cardiovascular and kidney disease in terms of the numbers of 
diabetes-related acute hospital admissions (Table 1) [6]. However, diabetes-related foot 
disease results in longer average length of hospital stay when compared to all other diabetes-
related complications (Table 1) [6]. Thus, it could be argued that in Australia diabetes-related 
foot complications consume the second largest amount of acute care resources of all diabetes 
complications behind only kidney disease when total hospital bed day usage is taken into 
account. A 2008 Australian study supports the contention that diabetes-related foot disease 
consumes the highest number of bed days annually, reporting 48 and 57 days respectively for 
admitted foot ulcers and amputations (compared to 18 days for myocardial infarction for 
example) [35]. Furthermore, the same study suggested that annual primary care resources (i.e. 
GP visits only) required to manage a diabetes complication for the year following an acute 
episode was highest for an acute foot complication; requiring an average of 18 GP visits for a 
foot ulcer [35]. 
How much do different acute diabetes complications cost in Australia? 
It has been reported that a person with diabetes (type 1 or type 2) without complications costs 
Australia around $3,500 to $4,000 per year in healthcare costs, and this escalates to around 
$7,000 for people with microvascular complications, and $16,700 per year in people with 
microvascular and macrovascular complications [13,36]. Acute foot complications (foot 
ulcers and amputations) are reported as having both a micro- and macrovascular component 
[13]. 
Table 2 displays costs associated with different diabetes-related complications broken down 
into hospital costs and non-hospital costs (medical and pharmaceutical costs only) for the 
initial year following a new acute complication and for each subsequent year after that in 
Australia. The literature suggests that amputations and foot ulcers are consistently the second 
and third most expensive acute diabetes complications respectively to treat in terms of both 
hospital and out-of-hospital costs [35]. Renal failure is by far the most expensive acute care 
complication and consumes further hospital resources via dialysis management [35,37]. 
Table 2 Comparison of specific costs for first diabetes complication episodes in Australia 
  Initial year of complication event Each subsequent year of complication event 
  Total $A 
2003 [37]* 
Total $A 1999 
[35]** 
Hospital $A 
1999 [35]** 
Non-hospital $A 
1999 [35]** 
Total $A 1999 
[35]** 
Hospital $A 
1999[35]** 
Non-hospital $A 
1999 [35]** 
CVD MI $15,611 $11,660 $10,836 $824 $2,701 $2,036 $665 
 CVA $17,073 $14,012 $13,032 $980 $3,691 $2,924 $767 
Kidney ESRF $34,991 $28,661 $27,820 $841 $30,612 $29,952 $660 
Eyes Blind $26,548 $8,880 $8,126 $754 $3,039 $2,425 $615 
Foot Amputations $23,555 $23,793 $22,991 $802 $6,065 $5,313 $751 
 Foot ulcer $14,691 $18,246 $17,357 $889 $4,761 $4,077 $684 
* Data converted from Euro to $A at 2012 rates (1 Euro = $1.27) 
** Note cost is the higher estimate from either a 60yo male or a 70yo male 
What is the burden of disease of the different diabetes complications in 
Australia? 
Australian burden of disease and mortality statistics (Table 1) demonstrate that foot 
complications rank second only to cardiovascular disease in terms of the effect all diabetes 
complications have on lost healthy years suffered by the Australian community [6]. Burden 
of disease can be summarised by disability adjusted life years (DALY) figures that determine 
total lost healthy life years in terms illness, injury and premature death [6]. Furthermore, 
mortality data associated with diabetes complications suggests foot complications are the 
second leading cause of diabetes-related death second only to cardiovascular disease; 
cardiovascular disease accounts for four-times the rate of any other diabetes cause [6]. 
How does the Australian government fund best-practice management of 
different diabetes complications? 
The Australian Government and NHMRC have regularly commissioned best-practice 
guidelines for the management of various diabetes complications [20-23]. Each guideline 
formulates recommendations (NHMRC graded) using standard evidence-based methods and 
are endorsed by NHMRC [20-23]. There are broad similarities in the recommendations 
emanating from the suite of diabetes complication guidelines including; screening every one 
to two years for complications, control of blood glucose levels, blood pressure and lipids, 
requirements for further investigations and/or surgical intervention for acute complications 
and a multi-disciplinary approach [20-23]. 
The cost of most of the NHMRC endorsed diabetes complication guideline recommendations 
are funded via the Australian Government‟s MBS or PBS programs [38,39]. The MBS 
Program, under the auspices of the Health Insurance Act 1973 (Cth) provides access to 
services via Medicare benefits which are claimable only for „clinically relevant‟ services 
provided by an appropriate health practitioner [38]. The PBS program, through the National 
Health Act 1953 (Cth), “provides timely, reliable and affordable access to necessary 
medicines for Australians” [39]. 
An examination of the best-practice guideline recommendations endorsed by the NHMRC for 
both assessment and management of diabetes and its complications reveals that all 
recommended assessments are publicly funded by the MBS scheme [20-23,38]. Interestingly, 
in terms of management of diabetes complications, it appears that all but possibly one of the 
recommendations outlined for cardiovascular, kidney or eye disease are funded via the MBS; 
the exception appears to be intravitreal triamcinolone for persistent diabetes macular 
degeneration management [20-23,38]. In contrast, it appears that at least five evidence-based 
recommendations outlined in the NHRMC diabetes guidelines to manage foot complications 
are not funded by the MBS [23,38]. These include: 
(i) total contact cast or other device rendered irremovable; 
(ii) topical hydrogel and wound dressings; 
(iii) appropriate footwear; 
(iv) topical negative pressure therapy; and 
(v) larval therapy for complex acute foot complication management [23,38]. 
Furthermore, it should be noted that the MBS schedule for podiatry consultation is capped at 
a maximum of five allied health consultations rebatable annually, and therefore, podiatry 
„competes‟ with all other allied health consultations [38]. Given that two other diabetes foot 
guideline recommendations specifically include the necessity for multiple podiatry review 
consultations in high-risk diabetes foot complication management and diabetes foot ulcer 
multi-disciplinary management, it could be argued that the current arrangements are 
inadequate to be considered satisfactorily publicly funded for seven diabetes-related foot 
recommendations [23,38]. 
An examination of all medications recommended for the management of diabetes-related 
complications suggests that all are publicly funded under the PBS system when prescribed by 
a medical or nurse endorsed prescriber [20-23,39,40]. Interestingly, many of those same 
recommended medications (particularly oral antibiotics for diabetes foot ulcer management) 
funded by PBS, are not covered by PBS when appropriately provided by an equivalent 
podiatry endorsed prescriber [39,40]. 
How is additional government funding distributed to address different 
diabetes complication management? 
In addition to PBS and MBS funding, the Federal Government in recent years has invested 
hundreds of millions of dollars into campaigns, programs, publications, research and/or 
additional resources (including capital and infrastructure) to manage the known 
complications of diabetes [41]. The distribution of this additional public funding for the 
management of diabetes complications appears to be more ad hoc, making it very difficult to 
make any direct comparison. However, a review of publicly available information from such 
sources as ministerial media releases, it appears that foot disease receives comparatively less 
support [41]. 
In reviewing the publicly available information, it is clear that the Australian Government has 
announced significant investment in the management of kidney, cardiovascular, and eye 
disease [41]. This includes in excess of $300 million to tackle kidney disease by funding the 
expansion of renal infrastructure, dialysis and support services across Australia and new 
drugs to combat kidney disease under the PBS [41]. Government has also allocated 
significant additional funding to combat cardiovascular disease, including up to $200 million 
for development and uptake of cardiovascular risk management tools and guidelines, 
investments in research, and establishment of a national centre for monitoring [41]. A number 
of cardiovascular disease initiatives have been federally funded through non-government 
organisations such as the Heart Foundation and the National Stroke Foundation [41]. A 
National Eye Framework has also been established with the responsibility for the funding of 
services to increase access to eye health and vision care [41]. Announcements to date include 
extra eye disease funding of up to $30 million, targeting increased consultation, training, 
equipment, surgical interventions and research to manage eye disease [41]. 
A search for similar Australian Government funding announcements over the last decade 
failed to identify any significant additional funding announcements specifically addressing 
foot or lower limb disease [41]. Furthermore, a cursory glance through the official Australian 
Institute of Health and Welfare (Australian Government funded) „diabetes related 
publications‟ webpage seems to also highlight this lack of comparative government focus on 
foot disease [42]. Of the 55 publications listed most are generically diabetes titled, with five 
titles specifically related to diabetes cardiovascular disease, four to kidney disease and none 
address foot disease [42]. 
Discussion 
This paper identifies that the burden of diabetes-related foot disease faced by the Australian 
population is the second largest of the four main diabetes complications in terms of burden of 
disease and numbers of people affected. In contrast, it appears that government funding of 
national best-practice management recommendations, and any additional government funding 
programs, ranks the funding of diabetes-related foot disease management as a distant last 
compared to the other diabetes complications. A summary of these findings can be found in 
Table 3. Therefore, the public funding and resources afforded to improve outcomes related to 
diabetes-related foot disease burden seems to be disproportionately low when compared to 
the burden and funding attributed to other more well-known diabetes complications in 
Australia. This anomaly should be considered in the context of the apparent increases in 
diabetes-related amputation in Australia over the last decade. 
Table 3 Summary of diabetes complication rankings in Australia 
 Burden and cost of complication Funding 
Rank Numbers 
affected
a
 
Costs per 
episode 
b
 
Overall 
estimated 
costs 
c
 
Proportion guideline 
recommendations funded 
d
 
Additional 
programs 
funded 
e
 
First CVD Kidney Kidney Kidney & CVD Kidney 
Second Foot Foot CVD  CVD 
Third Eyes Eyes Foot Eyes Eyes 
Fourth Kidney CVD Eyes Foot Foot 
a Numbers Affected: Mean% of the five parameters of High Risk and Acute complications in 
Table 1 
b Costs per Episode: Mean $cost of three „Total‟ cost parameters in Table 2 
c Overall estimated costs: Mean $cost of three „Total‟ cost parameters in Table 2 x Hospital 
admissions numbers in Table 1 
d Proportion guideline recommendations funded: Numbers of NHMRC endorsed diabetes 
complication guideline recommendations funded by MBS / Total number of NHMRC 
endorsed diabetes complication guideline recommendations 
e Additional Programs Funded: Additional total funding announcements of government in 
last 3 – 5 years 
Although it would appear that the Australian government has yet to specifically focus on 
reducing the burden of diabetes-related foot disease, there somewhat promisingly appears to 
have been an acceleration in the number of recent strategic publications released by national 
peak consumer, health professional and research bodies targeting the improvement in the 
prevention, assessment and management of diabetes-related foot disease [16,18,23,43]. Many 
of these documents cover the same territory in terms of recommendations to improve 
diabetes-related foot disease management and reduce the burden of diabetes-related foot 
ulceration and amputation in this country [16,18,23,43]. None, however, are yet to translate 
into public funding. 
The NHMRC endorsed diabetes foot guidelines compiled by national diabetes research, 
clinical and consumer experts, under the auspices of the Baker IDI Heart & Diabetes Institute 
and George Institute, suggest that “a co-ordinated, national, multi-faceted, systems approach 
for implementation (of the guideline) is considered essential” [23]. It recommends as high 
priorities for implementation: 
(i) 
funding and policy development to support timely access to health professionals and 
multi-disciplinary foot teams for people with high-risk and acute foot complications; in 
particular access to podiatrists, nurses and aboriginal health workers; 
(ii) 
further training for allied health professionals to assess ulcer risk, wound debridement, 
appropriate wound dressing and pressure reduction, and; 
(iii) 
electronic decision support tools for medical practitioners, allied health professionals and 
aboriginal health services [23]. 
The Australian Diabetes Society‟s Australian Diabetes Foot Network (ADFN), a multi-
disciplinary steering committee on diabetes-related foot disease, recently published a six 
point strategic plan to reduce Australian lower limb amputations in people with diabetes [16]. 
The plan, endorsed by the Australian Diabetes Society, Australasian Podiatry Council, 
Australian Diabetes Educators Association, Australian and New Zealand Society for Vascular 
Surgery, Australian Wound Management Association and Diabetes Australia, highlighted 
that the increase in diabetes-related foot disease in Australia “means a national focus on 
coordinated foot care is essential” [16]. Their six point strategic recommendations included: 
(i) improved access to foot care via MBS for people with foot complications; 
(ii) 
subsidies for evidence based treatments including pressure off-loading devices and 
medical grade footwear; 
(iii) standardised national model for multi-disciplinary foot teams 
(iv) national accreditation of multi-disciplinary foot clinics and health professionals; 
(v) 
improving holistic diabetes care initiatives to “close the gap” on inequities in diabetes 
foot outcomes for indigenous Australians, and; 
(vi) reporting of national incidence and outcomes of diabetes-related foot disease [16]. 
Interestingly, the previous Australian Diabetes Society (2000) [44] and national diabetes 
strategic plans (1998) [15], published over a decade ago, also included recommendations 
around routine podiatry care for people with high-risk feet, access to multidisciplinary team 
care for people with foot ulcers, increased access to foot care services for indigenous 
Australians, and a national diabetes foot care committee to oversee implementation of these 
national foot care activities and monitor outcomes [15,44]. The restatement of these same 
evidence-based strategies over 12 years on would seem to demonstrate the lack of systematic 
national implementation of these strategies and that existing arrangements have been 
insufficient in light of the increase in diabetes-related amputations over the same period. This 
lack of systematic investment seems to be in spite of the best efforts of the many 
multidisciplinary clinicians, health advocates and peak bodies. 
In an attempt to provide practical implementable solutions within the constraints of the 
current MBS and PBS systems, the Australasian Podiatry Council [18] submitted a costed 
budget submission to the Australian Government for consideration in the 2012 Australian 
Budget round [18]. The plan practically addressed four of the points of the ADFN plan [16], 
including: 
(i) implementing an annual national diabetes amputation rate report; 
(ii) 
increasing access to podiatrists via MBS from a maximum of 5 visits to an average of 12 
for those with diabetes-related foot complications and foot ulcers; 
(iii) subsidising pressure off-loading devices for those with past or present foot ulcers; and 
(iv) 
increasing access to MBS services for indigenous Australians with diabetes-related foot 
complications via indigenous health workers [18]. 
Subsequently, the peak national consumer body representing people with diabetes, Diabetes 
Australia, mirrored some of the recommendations of these plans in their recently released 
Diabetes National Election Agenda report (2012) [43]. The Diabetes Australia report 
addresses priorities for national implementation to improve the health of people living with 
diabetes, including: 
(i) increasing access to MBS allied health visits from 5 – 12 for people with diabetes; 
(ii) funding National Accredited Diabetes Centres (including multi-disciplinary teams), and; 
(iii) providing all people with diabetes a comprehensive annual risk assessment [43]. 
This translates to up to ten national peak health professional, research and consumer bodies 
recommending similar strategies to reduce diabetes-related foot complications and 
amputation in this country [16,18,23,43]. These common strategies seem to include: 
(i) 
increasing access to podiatry, nursing, indigenous health workers and other allied health 
services via MBS; 
(ii) 
subsidising evidenced-based treatments such as pressure off-loading devices via 
government funding; 
(iii) implementing standard models of multi-disciplinary foot care teams across the nation; 
(iv) reporting and monitoring of annual national diabetes foot disease rates, and; 
(v) urging the increased uptake of evidence-based guidelines [16,18,23,43]. 
These common strategies when implemented in other countries appear to significantly reduce 
diabetes-related amputation rates and costs [45-54]. Many other developed nations 
systematically implementing such evidence-based strategies display amputation rates 
approximately half that of Australia [12,18,33,34]. The UK has reported amputation rates as 
low as seven per 100,000 population [50,53] or nearly one third of the rate faced in Australia 
[17,18,34]. Furthermore, an international cost-utility analysis study concluded that just a 25% 
reduction in ulceration and amputation rates by implementing and funding best-practice 
systems to manage diabetes foot complications is a „cost-saving strategy‟ [55]. The 
Australasian Podiatry Council plan suggested that with the implementation of such strategies 
and assuming similar outcomes to those found in other nations, that an overall reduction in 
amputations and hospitalisation of between 24 to 90% was achievable in the Australian 
context [18]. This reduction translates to an estimated overall cost saving to Australia of $220 
to 400 million annually [18]. Thus, it would appear Australia could learn many lessons from 
other comparable nations that have invested in these well-known evidence-based strategies, 
which have reaped the associated benefits of reduced amputation, hospitalisation and cost for 
diabetes-related foot disease. 
Overall, the burden of diabetes-related foot disease in Australia is high and funding evidence-
based diabetes-related foot management seems to significantly reduce this burden when 
implemented in other comparable nations. This simple yet very effective strategy, of funding 
evidence-based recommendations, also appears to have enjoyed success in other Australian 
diabetes complications in terms of reducing devastating diabetes complication outcomes in 
Australia. It would therefore seem intuitive to follow this same strategy and ensure that at a 
minimum all national best-practice guideline recommendations on the management of 
diabetes complications are publicly funded to reduce the significant associated morbidity and 
mortality faced in Australia and improve the limbs and lives of Australians with diabetes. 
Conclusions 
Diabetes has been rated as one of the greatest public health challenges to face Australia. This 
paper has demonstrated that diabetes-related foot complications, in comparison to other 
diabetes complications, make up a considerable portion of the diabetes-related burden of 
disease in Australia. In contrast to other diabetes complications, it appears that a very low 
number of national best-practice recommendations have been incorporated into publicly 
funded models of care, and that foot disease lacks any additional public funding. These 
conspicuous gaps may significantly contribute to the poor outcomes of diabetes-related foot 
complications facing Australia in comparison to other Australian diabetes complications and 
international diabetes-related foot disease outcomes. In the spirit of unanimous UN action on 
diabetes, the promising diabetes-related foot results seen in other nations, and the constant 
urging of multiple diverse national peak bodies, it seems like “its time” to equally invest in 
diabetes-related foot disease in Australia. 
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